Stoichiometric gene-to-reaction associations enhance model-driven analysis performance: Metabolic response to chronic exposure to Aldrin in prostate cancer.
Endocrine disruptors
Genome-scale metabolic model
Prostate Cancer
Stoichiometric gene-protein-reaction association
Transcriptomic data integration
Journal
BMC genomics
ISSN: 1471-2164
Titre abrégé: BMC Genomics
Pays: England
ID NLM: 100965258
Informations de publication
Date de publication:
15 Aug 2019
15 Aug 2019
Historique:
received:
05
10
2018
accepted:
16
07
2019
entrez:
17
8
2019
pubmed:
17
8
2019
medline:
25
1
2020
Statut:
epublish
Résumé
Genome-scale metabolic models (GSMM) integrating transcriptomics have been widely used to study cancer metabolism. This integration is achieved through logical rules that describe the association between genes, proteins, and reactions (GPRs). However, current gene-to-reaction formulation lacks the stoichiometry describing the transcript copies necessary to generate an active catalytic unit, which limits our understanding of how genes modulate metabolism. The present work introduces a new state-of-the-art GPR formulation that considers the stoichiometry of the transcripts (S-GPR). As case of concept, this novel gene-to-reaction formulation was applied to investigate the metabolic effects of the chronic exposure to Aldrin, an endocrine disruptor, on DU145 prostate cancer cells. To this aim we integrated the transcriptomic data from Aldrin-exposed and non-exposed DU145 cells through S-GPR or GPR into a human GSMM by applying different constraint-based-methods. Our study revealed a significant improvement of metabolite consumption/production predictions when S-GPRs are implemented. Furthermore, our computational analysis unveiled important alterations in carnitine shuttle and prostaglandine biosynthesis in Aldrin-exposed DU145 cells that is supported by bibliographic evidences of enhanced malignant phenotype. The method developed in this work enables a more accurate integration of gene expression data into model-driven methods. Thus, the presented approach is conceptually new and paves the way for more in-depth studies of aberrant cancer metabolism and other diseases with strong metabolic component with important environmental and clinical implications.
Sections du résumé
BACKGROUND
BACKGROUND
Genome-scale metabolic models (GSMM) integrating transcriptomics have been widely used to study cancer metabolism. This integration is achieved through logical rules that describe the association between genes, proteins, and reactions (GPRs). However, current gene-to-reaction formulation lacks the stoichiometry describing the transcript copies necessary to generate an active catalytic unit, which limits our understanding of how genes modulate metabolism. The present work introduces a new state-of-the-art GPR formulation that considers the stoichiometry of the transcripts (S-GPR). As case of concept, this novel gene-to-reaction formulation was applied to investigate the metabolic effects of the chronic exposure to Aldrin, an endocrine disruptor, on DU145 prostate cancer cells. To this aim we integrated the transcriptomic data from Aldrin-exposed and non-exposed DU145 cells through S-GPR or GPR into a human GSMM by applying different constraint-based-methods.
RESULTS
RESULTS
Our study revealed a significant improvement of metabolite consumption/production predictions when S-GPRs are implemented. Furthermore, our computational analysis unveiled important alterations in carnitine shuttle and prostaglandine biosynthesis in Aldrin-exposed DU145 cells that is supported by bibliographic evidences of enhanced malignant phenotype.
CONCLUSIONS
CONCLUSIONS
The method developed in this work enables a more accurate integration of gene expression data into model-driven methods. Thus, the presented approach is conceptually new and paves the way for more in-depth studies of aberrant cancer metabolism and other diseases with strong metabolic component with important environmental and clinical implications.
Identifiants
pubmed: 31416420
doi: 10.1186/s12864-019-5979-4
pii: 10.1186/s12864-019-5979-4
pmc: PMC6694502
doi:
Substances chimiques
Endocrine Disruptors
0
Prostaglandins
0
Aldrin
OZE3CLY605
Carnitine
S7UI8SM58A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
652Subventions
Organisme : FP7 Ideas: European Research Council
ID : 320737
Organisme : Novo Nordisk Fonden
ID : NNF10CC1016517
Organisme : Novo Nordisk Fonden
ID : NNF14OC0009473
Références
J Comput Biol. 2012 Feb;19(2):102-14
pubmed: 22300313
Future Med Chem. 2014;6(16):1791-810
pubmed: 25574531
Transl Oncol. 2016 Aug;9(4):357-70
pubmed: 27567960
Nat Biotechnol. 2013 May;31(5):419-25
pubmed: 23455439
Front Bioeng Biotechnol. 2014 Dec 03;2:62
pubmed: 25520953
Nucleic Acids Res. 2016 Jan 4;44(D1):D471-80
pubmed: 26527732
Anal Bioanal Chem. 2016 Aug;408(21):5829-5841
pubmed: 27311955
Nucleic Acids Res. 1999 Jan 1;27(1):29-34
pubmed: 9847135
Environ Res. 2015 Jul;140:18-31
pubmed: 25817993
Nat Biotechnol. 2010 Mar;28(3):245-8
pubmed: 20212490
Eur J Biochem. 1997 Nov 15;250(1):1-6
pubmed: 9431984
Database (Oxford). 2015 Jul 24;2015:bav068
pubmed: 26209309
Nat Protoc. 2010 Jan;5(1):93-121
pubmed: 20057383
BJU Int. 2000 Mar;85(4):451-62
pubmed: 10691825
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14
pubmed: 21980008
Front Oncol. 2016 Nov 16;6:244
pubmed: 27900284
Nat Commun. 2014;5:3083
pubmed: 24419221
Arterioscler Thromb Vasc Biol. 2017 May;37(5):856-866
pubmed: 28254818
Genome Res. 2004 May;14(5):925-8
pubmed: 15078858
PLoS Comput Biol. 2008 May 16;4(5):e1000082
pubmed: 18483554
Science. 2012 May 25;336(6084):1040-4
pubmed: 22628656
PLoS Comput Biol. 2018 Jan 2;14(1):e1005914
pubmed: 29293497
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Indian J Cancer. 2016 Jul-Sep;53(3):441-442
pubmed: 28244479
Bioinformatics. 2010 Dec 15;26(24):3140-2
pubmed: 21081510
BMC Bioinformatics. 2011 Jan 22;12:28
pubmed: 21255455
Nucleic Acids Res. 2011 Jan;39(Database issue):D691-7
pubmed: 21067998
Curr Opin Genet Dev. 2017 Apr;43:120-127
pubmed: 28363112
Mol Syst Biol. 2016 Oct 20;12(10):883
pubmed: 27951527
Mol Syst Biol. 2010 Jul;6:390
pubmed: 20664636
Int J Mol Sci. 2016 Jul 02;17(7):
pubmed: 27384557
Nucleic Acids Res. 2013 Jan;41(Database issue):D801-7
pubmed: 23161693
Genome Inform. 2007;18:308-19
pubmed: 18546498
Front Physiol. 2015 Dec 16;6:382
pubmed: 26733270
PLoS Comput Biol. 2014 Apr 24;10(4):e1003580
pubmed: 24762745
Bioinformatics. 2011 Feb 15;27(4):541-7
pubmed: 21172910
Korean J Anesthesiol. 2015 Dec;68(6):540-6
pubmed: 26634076
Int J Cell Biol. 2012;2012:723419
pubmed: 22505934
J Lipid Res. 2009 Apr;50 Suppl:S9-14
pubmed: 19098281
Oncoimmunology. 2017 Jun 28;6(8):e1338239
pubmed: 28920002
Anal Chem. 2011 May 1;83(9):3406-14
pubmed: 21456517